ClinicalTrials.gg
CompletedNCT05281523ANCHOR-2Updated Sep 9, 2025Results posted

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

A Phase 3 interventional study of Depemokimab (GSK3511294) and Placebo in Nasal Polyps, sponsored by GlaxoSmithKline. Completed at 84 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Enrollment
13th of 71
264 · median 60
Started
2022
with 5 others
Phase 3
25 of 83
4 open now
Registered
60th of 83
by date
Lead sponsor
5 of 83
GlaxoSmithKline

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 13th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2022, is one of 25 in phase 3, and was the 60th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).

03

Conditions studied

  • Nasal Polyps

Browse trials for

Keywords

  • Depemokimab
  • GSK3511294
  • Chronic rhinosinusitis
  • Verbal response scale
  • Asthma Control Questionnaire
  • Lund Mackay computed tomography
  • Nasal polyps score
  • Nasal endoscopy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria:

  • Participants with 18 years of age and older inclusive, at the time of signing the .
  • Endoscopic bilateral NP score of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity) assessed by the investigator.
  • Participants who have had at least one of the following at Visit 1: Previous nasal surgery for the removal of NP; Have used at least three consecutive days of systemic in the previous 2 years for the treatment of NP; Medically unsuitable or intolerant to systemic corticosteroid.
  • Participants (except for those in Japan) must be on daily treatment with intranasal corticosteroids (INCS) (including intranasal liquid steroid wash/douching) for at least 8 weeks prior to screening.
  • Participants presenting with severe NP symptoms defined as symptoms of nasal congestion/blockade/obstruction with moderate or severe severity and loss of smell or rhinorrhea (runny nose) based on clinical assessment by the investigator.
  • Presence of symptoms of chronic rhinosinusitis as described by at least 2 different symptoms for at least 12 weeks prior to Visit 1, one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip), plus facial pain/pressure and/or reduction or loss of smell.
  • Male or eligible female participants

Exclusion Criteria:

Exclusion Criteria:

  • As a result of medical interview, physical examination, or screening investigation the physician responsible considers the participant unfit for the study.
  • Cystic fibrosis.
  • Antrochoanal polyps.
  • Nasal cavity tumor (malignant or benign)
  • Fungal rhinosinusitis
  • Severe nasal septal deviation occluding one nostril preventing full assessment of nasal polyps in both nostrils.
  • Participants who had a sino-nasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of nasal polyp score.
  • Acute sinusitis or upper respiratory tract infection (URTI) at screening or in 2 weeks prior to screening.
  • Ongoing rhinitis medicamentosa (rebound or chemical induced rhinitis).
  • Participants who have had an asthma exacerbation requiring admission to hospital within 4 weeks of Screening.
  • Participants who have undergone any intranasal and/or sinus surgery (for example polypectomy, balloon dilatation or nasal stent insertion) within 6 months prior to Visit 1; nasal prior to Visit 1 for diagnostic purposes only is excepted.
  • Participants where NP surgery is in the opinion of the Investigator.
  • Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) eosinophilic granulomatosis with polyangiitis (EGPA) (formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis.
  • Participants with a known, pre-existing parasitic infestation within 6 months prior to Visit 1.
  • A known immunodeficiency (e.g. (HIV), other than that explained by the use of corticosteroids (CSs) taken as therapy for asthma.
  • A current or previous history of cancer in remission for less than 12 months prior to screening.
  • Liver Disease: (ALT) >2 times upper limit normal (); Total >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin less than [\<]35 percent [%]); Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
  • Participants who have known, pre-existing, cardiac, endocrine, , metabolic, neurological, renal, gastrointestinal, hepatic, hematological or any other system abnormalities that are uncontrolled with standard treatment.
  • Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis must be excluded prior to enrollment.
  • : Participants with allergy/intolerance to the of depemokimab (GSK3511294) in a monoclonal antibody, or biologic.
  • Participants that, according to the investigator's medical judgment, are likely to have active Coronavirus disease-2019 (COVID-19) infection must be excluded. Participants with known COVID-19 positive contacts within the past 14 days must be excluded for at least 14 days following the exposure during which the participant should remain symptom-free. Reported smell/ taste complications from COVID-19 must be used as exclusion.
  • Participants that have been exposed to ionising radiation in excess of 10 millisievert (mSv) above background over the previous 3-year period as a result of occupational exposure or previous participation in research studies.
  • Previously participated in any study with mepolizumab, reslizumab, or benralizumab and received study intervention (including placebo) within 12 months prior to Visit 1.
  • Women who are pregnant or lactating or are planning on becoming pregnant during the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
264 participants (actual)

Study arms

  • Experimental
    Depemokimab

    Participants received a 100 milligram (mg) dose of depemokimab subcutaneous (SC) injection once every 26 weeks (week 0 and week 26) over a treatment period of 52-weeks. Participants were to be maintained on their existing baseline maintenance Chronic rhinosinusitis with nasal polyps (CRSwNP) standard of care (SOC) treatment throughout the study.

    Biological: Depemokimab (GSK3511294)

  • Placebo comparator
    Placebo

    Participants received placebo SC injection once every 26 weeks (week 0 and week 26) over a treatment period of 52-weeks. Participants were to be maintained on their existing baseline maintenance CRSwNP SOC treatment throughout the study.

    Drug: Placebo

Interventions

  • Depemokimab (GSK3511294) was administered using a pre-filled syringe.

  • DrugPlacebo

    Placebo was administered as normal saline using a pre-filled syringe.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read)

    Total endoscopic nasal polyps (NP) score evaluated the size and extent of nasal polyps via endoscopy. The assessments were performed by central video image recordings of nasal endoscopy. The right and left nostrils were scored from 0 to 4 (0 = No polyps; 1 = Small polyps in the middle meatus not reaching below the inferior border of the middle concha; 2 = Polyps reaching below the lower border of the middle turbinate; 3 = Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle concha; and 4 = Large polyps causing complete obstruction of the inferior meatus). The scores were graded based on NP size, recorded as sum of the right and left nostril scores and ranges from 0 (no polyps) to 8 (large polyps), calculated by summing the scores \[0 to 4\] in each nostril; with higher scores indicating worse status. Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

    Time frame: Baseline (Day 1) and at Week 52

  2. Change From Baseline in Mean Nasal Obstruction Score Using Verbal Response Scale From Weeks 49 Through to Week 52

    This endpoint evaluated the change from baseline in the mean nasal obstruction score using a Verbal Response Scale (VRS) from Week 49 through to Week 52. Participants used a VRS to rate nasal obstruction severity, with scores averaged over the specified period to assess treatment impact on nasal obstruction symptoms. Participants were asked to indicate the severity of nasal obstruction at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This was scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms), with higher scores indicating worse status. Baseline was defined as the average score from 28 days of eDiary data collected prior to Day 1. Change from Baseline = Post-baseline value minus Baseline value.

    Time frame: Baseline (Day 1) and from Week 49 to Week 52

Secondary outcomes

  1. Change From Baseline in Mean Symptom Score for Rhinorrhea (Runny Nose) Using Verbal Response Scale From Week 49 Through to Week 52

    Participants were asked to indicate the severity of rhinorrhea (runny nose) at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This was scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms). Higher scores indicated worst status. The average of daily scores in 4-weekly intervals were calculated and change from baseline data are presented for Weeks 49-52. Baseline was defined as the average score from 28 days of eDiary data collected prior to Day 1. Change from Baseline = Post-baseline value minus Baseline value.

    Time frame: Baseline (Day 1) and from Week 49 to Week 52

  2. Change From Baseline in Mean Symptom Score for Loss of Smell From Week 49 Through to Week 52

    Participants were asked to indicate the severity of loss of smell at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This was scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms). Higher score indicates worse status. The average of daily scores in 4-weekly intervals were calculated and change from baseline data are presented for Weeks 49-52. Baseline was defined as the average score from 28 days of eDiary data collected prior to Day 1. Change from Baseline = Post-baseline value minus Baseline value.

    Time frame: Baseline (Day 1) and from Week 49 to Week 52

  3. Change From Baseline in Lund Mackay (LMK) Computed Tomography (CT) Score at Week 52

    The LMK CT scoring system is based on CT imaging of the sinuses with points given for degree of opacification: 0 =normal, 1 = partial opacification, 2 = total opacification. These points were applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side (right and left). The osteomeatal complex (OC) is graded as 0 = not occluded, or 2 = occluded. The range for the total LMK CT score is therefore 0 (normal) to 24 (total opacification) when summed across both sides with higher scores indicating more severe disease. Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

    Time frame: Baseline (Day 1) and at Week 52

  4. Change From Baseline in Sino-nasal Outcome Test (SNOT)-22 Total Score at Week 52

    Sino-nasal outcome test-22 is a 22-item measure of disease specific health related quality of life (HRQoL). Participants were asked to rate the severity of their condition on each of the 22 items over the previous 2 weeks using a 6-point rating scale of 0-5 including: 0 = Not present/no problem; 1 = Very mild problem; 2 = Mild or slight problem; 3 = Moderate problem; 4 = Severe problem; 5 = Problem as "bad as it can be". The scores for each question were summed up to derive the total score range for the SNOT-22 was from 0 (high quality of life) to 110 (worst quality of life), where higher scores indicate worse quality of life. Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

    Time frame: Baseline (Day 1) and at Week 52

  5. Change From Baseline in Mean Nasal Obstruction Score From Week 21 Through to Week 24

    Participants were asked to indicate the severity of nasal obstruction at its worst over the previous 24 hours using a 4-point VRS. The response options were no symptoms, mild symptoms, moderate symptoms, and severe symptoms, scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms). Higher scores indicate more severe status. The average of daily scores in 4-weekly intervals were calculated and change from baseline data are presented for Weeks 21-24. Baseline was defined as the average score from 28 days of eDiary data collected prior to Day 1. Change from Baseline = Post-baseline value minus Baseline value.

    Time frame: Baseline (Day 1) and from Week 21 to Week 24

  6. Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 26

    Total endoscopic nasal polyps (NP) score evaluated the size and extent of nasal polyps via endoscopy. The assessments were performed by central video image recordings of nasal endoscopy. The right and left nostrils were scored from 0 to 4 (0 = No polyps; 1 = Small polyps in the middle meatus not reaching below the inferior border of the middle concha; 2 = Polyps reaching below the lower border of the middle turbinate; 3 = Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle concha; and 4 = Large polyps causing complete obstruction of the inferior meatus). The scores were graded based on NP size, recorded as sum of the right and left nostril scores and ranges from 0 (no polyps) to 8 (large polyps), calculated by summing the scores \[0 to 4\] in each nostril; with higher scores indicating worse status. Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

    Time frame: Baseline (Day 1) and at Week 26

  7. Percentage of Participants Requiring First Nasal Surgery (Actual or Entry on Waiting List) or Disease-Modulating Medication for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Up to Week 52

    Nasal polyp surgery is defined as any procedure involving instruments resulting in incision and removal of tissue from the nasal cavity (for example polypectomy). Time to first nasal polyp surgery (actual or entry on waiting list) or disease-modulating medication for CRSwNP up to Week 52 was assessed in a pre-specified pooled analysis across replicate studies 217095 (NCT05274750) and 218079 (NCT05281523). The percentage of participants with nasal surgery or disease-modulating medication for CRSwNP and corresponding 95% CI have been presented, calculated using the Kaplan-Meier method.

    Time frame: Up to Week 52

  8. Percentage of Participants Requiring First Nasal Surgery (Actual) or Disease-Modulating Medication for CRSwNP up to Week 52

    Nasal polyp surgery is defined as any procedure involving instruments resulting in incision and removal of tissue from the nasal cavity (for example polypectomy).Time to first nasal polyp surgery (actual) or disease-modulating medication for CRSwNP up to week 52 was assessed in a pre-specified pooled analysis across replicate studies 217095 (NCT05274750) and 218079 (NCT05281523). The percentage of participants with nasal surgery or disease-modulating medication for CRSwNP and corresponding 95% CI have been presented, calculated using the Kaplan-Meier method.

    Time frame: Up to Week 52

  9. Percentage of Participants Requiring at Least One Course of Systemic Corticosteroids or Disease-Modulating Medication for CRSwNP or Nasal Surgery (Actual) During the Week 52 Treatment Period

    The percentage of participants requiring at least 1 course of systemic corticosteroids or disease-modulating medication for CRSwNP or nasal surgery (actual) during the Week 52 treatment period was assessed in a pre-specified pooled analysis across replicate studies 217095 (NCT05274750) and 218079 (NCT05281523). Percentage of participants with nasal surgery or course of systemic CS for CRSwNP and corresponding 95% CI have been presented, calculated using the Kaplan-Meier method.

    Time frame: Up to Week 52

  10. Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52

    The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower scores with better asthma control. Impact on asthma control in the subgroup of participants with an ACQ-5 score greater than 0.75 (indicating partially or not well-controlled) at baseline was assessed in a pre-specified pooled analysis across replicate studies 217095 (NCT05274750) and 218079 (NCT05281523). Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

    Time frame: Baseline (Day 1) and at Week 52

07

Results

Posted Sep 9, 2025

Participant flow

A total of 264 participants were randomized to the study. Of which 257 participants were included in the Full Analysis Set (FAS) population. The FAS included all randomized participants who received at least 1 dose of study intervention excluding 7 participants from 2 sites with Good Clinical Practice (GCP)/data integrity issues.

Participant flow — Overall Study
MilestoneDepemokimabPlacebo
Started132132
Full analysis population129128
Completed122111
Not completed1021
Withdrew: Adverse event11
Withdrew: Physician decision11
Withdrew: Withdrawal by subject515
Withdrew: Gcp violations34

Outcome measures

PrimaryChange From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read)

Total endoscopic nasal polyps (NP) score evaluated the size and extent of nasal polyps via endoscopy. The assessments were performed by central video image recordings of nasal endoscopy. The right and left nostrils were scored from 0 to 4 (0 = No polyps; 1 = Small polyps in the middle meatus not reaching below the inferior border of the middle concha; 2 = Polyps reaching below the lower border of the middle turbinate; 3 = Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle concha; and 4 = Large polyps causing complete obstruction of the inferior meatus). The scores were graded based on NP size, recorded as sum of the right and left nostril scores and ranges from 0 (no polyps) to 8 (large polyps), calculated by summing the scores \[0 to 4\] in each nostril; with higher scores indicating worse status. Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Least squares mean · Scores on scale
Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read)
Scores on scaleDepemokimabPlacebo
Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read)-0.5 ± 0.140.1 ± 0.15
Statistical analysis
  • Depemokimab vs Placebo · Mixed Models Analysis · p = 0.004 · Difference in least square means: -0.6 · 95% CI -1.0 to -0.2
PrimaryChange From Baseline in Mean Nasal Obstruction Score Using Verbal Response Scale From Weeks 49 Through to Week 52

This endpoint evaluated the change from baseline in the mean nasal obstruction score using a Verbal Response Scale (VRS) from Week 49 through to Week 52. Participants used a VRS to rate nasal obstruction severity, with scores averaged over the specified period to assess treatment impact on nasal obstruction symptoms. Participants were asked to indicate the severity of nasal obstruction at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This was scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms), with higher scores indicating worse status. Baseline was defined as the average score from 28 days of eDiary data collected prior to Day 1. Change from Baseline = Post-baseline value minus Baseline value.

Time frame:
Baseline (Day 1) and from Week 49 to Week 52
Reported as:
Least squares mean · Scores on scale
Change From Baseline in Mean Nasal Obstruction Score Using Verbal Response Scale From Weeks 49 Through to Week 52
Scores on scaleDepemokimabPlacebo
Change From Baseline in Mean Nasal Obstruction Score Using Verbal Response Scale From Weeks 49 Through to Week 52-0.77 ± 0.076-0.53 ± 0.078
Statistical analysis
  • Depemokimab vs Placebo · Mixed Models Analysis · p = 0.025 · Difference in least square means: -0.25 · 95% CI -0.46 to -0.03
SecondaryChange From Baseline in Mean Symptom Score for Rhinorrhea (Runny Nose) Using Verbal Response Scale From Week 49 Through to Week 52

Participants were asked to indicate the severity of rhinorrhea (runny nose) at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This was scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms). Higher scores indicated worst status. The average of daily scores in 4-weekly intervals were calculated and change from baseline data are presented for Weeks 49-52. Baseline was defined as the average score from 28 days of eDiary data collected prior to Day 1. Change from Baseline = Post-baseline value minus Baseline value.

Time frame:
Baseline (Day 1) and from Week 49 to Week 52
Reported as:
Least squares mean · Scores on scale
Change From Baseline in Mean Symptom Score for Rhinorrhea (Runny Nose) Using Verbal Response Scale From Week 49 Through to Week 52
Scores on scaleDepemokimabPlacebo
Change From Baseline in Mean Symptom Score for Rhinorrhea (Runny Nose) Using Verbal Response Scale From Week 49 Through to Week 52-0.72 ± 0.080-0.54 ± 0.082
Statistical analysis
  • Depemokimab vs Placebo · Mixed Models Analysis · p = 0.125 · Difference in least square means: -0.18 · 95% CI -0.40 to 0.05
SecondaryChange From Baseline in Mean Symptom Score for Loss of Smell From Week 49 Through to Week 52

Participants were asked to indicate the severity of loss of smell at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This was scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms). Higher score indicates worse status. The average of daily scores in 4-weekly intervals were calculated and change from baseline data are presented for Weeks 49-52. Baseline was defined as the average score from 28 days of eDiary data collected prior to Day 1. Change from Baseline = Post-baseline value minus Baseline value.

Time frame:
Baseline (Day 1) and from Week 49 to Week 52
Reported as:
Least squares mean · Scores on scale
Change From Baseline in Mean Symptom Score for Loss of Smell From Week 49 Through to Week 52
Scores on scaleDepemokimabPlacebo
Change From Baseline in Mean Symptom Score for Loss of Smell From Week 49 Through to Week 52-0.56 ± 0.066-0.30 ± 0.068
Statistical analysis
  • Depemokimab vs Placebo · Mixed Models Analysis · p = 0.007 · Difference in least square means: -0.26 · 95% CI -0.45 to -0.07
SecondaryChange From Baseline in Lund Mackay (LMK) Computed Tomography (CT) Score at Week 52

The LMK CT scoring system is based on CT imaging of the sinuses with points given for degree of opacification: 0 =normal, 1 = partial opacification, 2 = total opacification. These points were applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side (right and left). The osteomeatal complex (OC) is graded as 0 = not occluded, or 2 = occluded. The range for the total LMK CT score is therefore 0 (normal) to 24 (total opacification) when summed across both sides with higher scores indicating more severe disease. Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Least squares mean · Scores on scale
Change From Baseline in Lund Mackay (LMK) Computed Tomography (CT) Score at Week 52
Scores on scaleDepemokimabPlacebo
Change From Baseline in Lund Mackay (LMK) Computed Tomography (CT) Score at Week 52-3.5 ± 0.42-0.3 ± 0.44
Statistical analysis
  • Depemokimab vs Placebo · ANCOVA · p = <0.001 · Difference in least square means: -3.2 · 95% CI -4.4 to -2.0
SecondaryChange From Baseline in Sino-nasal Outcome Test (SNOT)-22 Total Score at Week 52

Sino-nasal outcome test-22 is a 22-item measure of disease specific health related quality of life (HRQoL). Participants were asked to rate the severity of their condition on each of the 22 items over the previous 2 weeks using a 6-point rating scale of 0-5 including: 0 = Not present/no problem; 1 = Very mild problem; 2 = Mild or slight problem; 3 = Moderate problem; 4 = Severe problem; 5 = Problem as "bad as it can be". The scores for each question were summed up to derive the total score range for the SNOT-22 was from 0 (high quality of life) to 110 (worst quality of life), where higher scores indicate worse quality of life. Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Least squares mean · Scores on scale
Change From Baseline in Sino-nasal Outcome Test (SNOT)-22 Total Score at Week 52
Scores on scaleDepemokimabPlacebo
Change From Baseline in Sino-nasal Outcome Test (SNOT)-22 Total Score at Week 52-15.9 ± 2.83-6.0 ± 2.87
Statistical analysis
  • Depemokimab vs Placebo · Mixed Models Analysis · p = 0.015 · Difference in least square means: -9.9 · 95% CI -17.9 to -2.0
SecondaryChange From Baseline in Mean Nasal Obstruction Score From Week 21 Through to Week 24

Participants were asked to indicate the severity of nasal obstruction at its worst over the previous 24 hours using a 4-point VRS. The response options were no symptoms, mild symptoms, moderate symptoms, and severe symptoms, scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms). Higher scores indicate more severe status. The average of daily scores in 4-weekly intervals were calculated and change from baseline data are presented for Weeks 21-24. Baseline was defined as the average score from 28 days of eDiary data collected prior to Day 1. Change from Baseline = Post-baseline value minus Baseline value.

Time frame:
Baseline (Day 1) and from Week 21 to Week 24
Reported as:
Least squares mean · Scores on scale
Change From Baseline in Mean Nasal Obstruction Score From Week 21 Through to Week 24
Scores on scaleDepemokimabPlacebo
Change From Baseline in Mean Nasal Obstruction Score From Week 21 Through to Week 24-0.78 ± 0.068-0.54 ± 0.069
Statistical analysis
  • Depemokimab vs Placebo · Mixed Models Analysis · p = 0.016 · Difference in least square means: -0.24 · 95% CI -0.43 to -0.04
SecondaryChange From Baseline in Total Endoscopic Nasal Polyps Score at Week 26

Total endoscopic nasal polyps (NP) score evaluated the size and extent of nasal polyps via endoscopy. The assessments were performed by central video image recordings of nasal endoscopy. The right and left nostrils were scored from 0 to 4 (0 = No polyps; 1 = Small polyps in the middle meatus not reaching below the inferior border of the middle concha; 2 = Polyps reaching below the lower border of the middle turbinate; 3 = Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle concha; and 4 = Large polyps causing complete obstruction of the inferior meatus). The scores were graded based on NP size, recorded as sum of the right and left nostril scores and ranges from 0 (no polyps) to 8 (large polyps), calculated by summing the scores \[0 to 4\] in each nostril; with higher scores indicating worse status. Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

Time frame:
Baseline (Day 1) and at Week 26
Reported as:
Least squares mean · Scores on scale
Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 26
Scores on scaleDepemokimabPlacebo
Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 26-0.5 ± 0.12-0.1 ± 0.12
Statistical analysis
  • Depemokimab vs Placebo · Mixed Models Analysis · p = 0.066 · Difference in least square means: -0.3 · 95% CI -0.7 to 0.0
SecondaryPercentage of Participants Requiring First Nasal Surgery (Actual or Entry on Waiting List) or Disease-Modulating Medication for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Up to Week 52

Nasal polyp surgery is defined as any procedure involving instruments resulting in incision and removal of tissue from the nasal cavity (for example polypectomy). Time to first nasal polyp surgery (actual or entry on waiting list) or disease-modulating medication for CRSwNP up to Week 52 was assessed in a pre-specified pooled analysis across replicate studies 217095 (NCT05274750) and 218079 (NCT05281523). The percentage of participants with nasal surgery or disease-modulating medication for CRSwNP and corresponding 95% CI have been presented, calculated using the Kaplan-Meier method.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring First Nasal Surgery (Actual or Entry on Waiting List) or Disease-Modulating Medication for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Up to Week 52
Percentage of participantsPooled DepemokimabPooled Placebo
Percentage of Participants Requiring First Nasal Surgery (Actual or Entry on Waiting List) or Disease-Modulating Medication for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Up to Week 5215.0 (11.3 to 19.9)21.9 (17.2 to 27.7)
Statistical analysis
  • Pooled Depemokimab vs Pooled Placebo · Cox Proportional Hazards Model · p = 0.128 · Hazard ratio (hr): 0.735 · 95% CI 0.495 to 1.092
SecondaryPercentage of Participants Requiring First Nasal Surgery (Actual) or Disease-Modulating Medication for CRSwNP up to Week 52

Nasal polyp surgery is defined as any procedure involving instruments resulting in incision and removal of tissue from the nasal cavity (for example polypectomy).Time to first nasal polyp surgery (actual) or disease-modulating medication for CRSwNP up to week 52 was assessed in a pre-specified pooled analysis across replicate studies 217095 (NCT05274750) and 218079 (NCT05281523). The percentage of participants with nasal surgery or disease-modulating medication for CRSwNP and corresponding 95% CI have been presented, calculated using the Kaplan-Meier method.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring First Nasal Surgery (Actual) or Disease-Modulating Medication for CRSwNP up to Week 52
Percentage of participantsPooled DepemokimabPooled Placebo
Percentage of Participants Requiring First Nasal Surgery (Actual) or Disease-Modulating Medication for CRSwNP up to Week 5212.2 (8.8 to 16.8)16.7 (12.6 to 22.0)
Statistical analysis
  • Pooled Depemokimab vs Pooled Placebo · Cox Proportional Hazards Model · p = 0.146 · Hazard ratio (hr): 0.713 · 95% CI 0.453 to 1.124
SecondaryPercentage of Participants Requiring at Least One Course of Systemic Corticosteroids or Disease-Modulating Medication for CRSwNP or Nasal Surgery (Actual) During the Week 52 Treatment Period

The percentage of participants requiring at least 1 course of systemic corticosteroids or disease-modulating medication for CRSwNP or nasal surgery (actual) during the Week 52 treatment period was assessed in a pre-specified pooled analysis across replicate studies 217095 (NCT05274750) and 218079 (NCT05281523). Percentage of participants with nasal surgery or course of systemic CS for CRSwNP and corresponding 95% CI have been presented, calculated using the Kaplan-Meier method.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring at Least One Course of Systemic Corticosteroids or Disease-Modulating Medication for CRSwNP or Nasal Surgery (Actual) During the Week 52 Treatment Period
Percentage of participantsPooled DepemokimabPooled Placebo
Percentage of Participants Requiring at Least One Course of Systemic Corticosteroids or Disease-Modulating Medication for CRSwNP or Nasal Surgery (Actual) During the Week 52 Treatment Period2636
Statistical analysis
  • Pooled Depemokimab vs Pooled Placebo · Regression, Logistic · p = 0.006 · Odds ratio (or): 0.58 · 95% CI 0.40 to 0.86
SecondaryChange From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower scores with better asthma control. Impact on asthma control in the subgroup of participants with an ACQ-5 score greater than 0.75 (indicating partially or not well-controlled) at baseline was assessed in a pre-specified pooled analysis across replicate studies 217095 (NCT05274750) and 218079 (NCT05281523). Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Least squares mean · Scores on scale
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52
Scores on scalePooled DepemokimabPooled Placebo
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52-0.75 ± 0.1820.00 ± 0.182
Statistical analysis
  • Pooled Depemokimab vs Pooled Placebo · Mixed Models Analysis · p = 0.004 · Difference in least square means: -0.75 · 95% CI -1.26 to -0.25

Adverse events

Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study intervention (Day 1) until follow up week 56.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Depemokimab0/129 (0%)6/129 (4.7%)75/129 (58.1%)
Placebo0/128 (0%)10/128 (7.8%)78/128 (60.9%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventDepemokimabPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders0/1292/128
Angina unstableCardiac disorders0/1291/128
PancreatitisGastrointestinal disorders0/1291/128
Biliary dilatationHepatobiliary disorders0/1291/128
Cholecystitis acuteHepatobiliary disorders0/1291/128
Chronic sinusitisInfections and infestations0/1291/128
PneumoniaInfections and infestations1/1291/128
Radius fractureInjury, poisoning and procedural complications0/1291/128
Rib fractureInjury, poisoning and procedural complications0/1291/128
Sternal fractureInjury, poisoning and procedural complications0/1291/128
Most frequent other events
Showing 10 of 16
Most frequent other events
EventDepemokimabPlacebo
NasopharyngitisInfections and infestations28/12915/128
Upper respiratory tract infectionInfections and infestations14/12915/128
Nasal congestionRespiratory, thoracic and mediastinal disorders5/12914/128
HeadacheNervous system disorders11/12913/128
COVID-19Infections and infestations9/12911/128
Nasal polypsRespiratory, thoracic and mediastinal disorders7/12911/128
Back painMusculoskeletal and connective tissue disorders3/1298/128
CoughRespiratory, thoracic and mediastinal disorders5/1298/128
ArthralgiaMusculoskeletal and connective tissue disorders3/1296/128
AsthmaRespiratory, thoracic and mediastinal disorders2/1296/128

Baseline characteristics

The full analysis set population included all randomized participants who received at least one dose of study intervention excluding participants from 2 sites with GCP violation. Participants were analyzed according to the intervention they were allocated at randomization.

Age, Continuous
Age, Continuous(YEARS)DepemokimabPlaceboTotal
Mean50.5 ± 12.9550.4 ± 12.9850.4 ± 12.94
Sex: Female, Male
Sex: Female, Male(Participants)DepemokimabPlaceboTotal
Female404080
Male8988177
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DepemokimabPlaceboTotal
ASIAN272653
WHITE9998197
ALL OTHER RACES347
08

Study locations

84 sites
  • GSK Investigational Site
    Tucson, Arizona 85724, United States
  • GSK Investigational Site
    Roseville, California 95661, United States
  • GSK Investigational Site
    New Haven, Connecticut 06520, United States
  • GSK Investigational Site
    Hialeah, Florida 33012, United States
  • GSK Investigational Site
    Baltimore, Maryland 21287, United States
  • GSK Investigational Site
    Grand Rapids, Michigan 55446, United States
  • GSK Investigational Site
    Columbia, Missouri 65212, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • GSK Investigational Site
    Fort Worth, Texas 76109, United States
  • GSK Investigational Site
    McAllen, Texas 78503, United States
  • GSK Investigational Site
    McKinney, Texas 75070, United States
  • GSK Investigational Site
    San Antonio, Texas 78258, United States
  • GSK Investigational Site
    Norfolk, Virginia 23507, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26506-9200, United States
  • GSK Investigational Site
    Changsha, 410013, China
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Guangzhou, 510000, China
  • GSK Investigational Site
    Hangzhou, 310000, China
  • GSK Investigational Site
    Nanjing, 210009, China
  • GSK Investigational Site
    Shanghai, 200003, China
  • GSK Investigational Site
    Shanghai, 200031, China
  • GSK Investigational Site
    Suzhou, China
  • GSK Investigational Site
    Wuhan, 430060, China
  • GSK Investigational Site
    Xiamen, 361004, China
  • GSK Investigational Site
    Zhongshan, 528400, China
  • GSK Investigational Site
    Zibo Shandong Province, 255036, China
  • GSK Investigational Site
    Bologna, 40139, Italy
  • GSK Investigational Site
    Catania, 95123, Italy
  • GSK Investigational Site
    Milan, 20132, Italy
  • GSK Investigational Site
    Naples, 80131, Italy
  • GSK Investigational Site
    Padova, 35100, Italy
  • GSK Investigational Site
    Pisa, Italy
  • GSK Investigational Site
    Roma, 00128, Italy
  • GSK Investigational Site
    Roma, 00168, Italy
  • GSK Investigational Site
    Rozzano MI, 20089, Italy
  • GSK Investigational Site
    Varese, 21100, Italy
  • GSK Investigational Site
    Aichi, 471-8513, Japan
  • GSK Investigational Site
    Chiba, 262-0015, Japan
  • GSK Investigational Site
    Chiba, 272-0143, Japan
  • GSK Investigational Site
    Gunma, 373-8585, Japan
  • GSK Investigational Site
    Hyōgo, 650-0047, Japan
  • GSK Investigational Site
    Hyōgo, 665-0827, Japan
  • GSK Investigational Site
    Ibaraki, 309-1793, Japan
  • GSK Investigational Site
    Kanagawa, 211-8533, Japan
  • GSK Investigational Site
    Nagano, 395-8505, Japan
  • GSK Investigational Site
    Shiga, 525-8585, Japan
  • GSK Investigational Site
    Shizuoka, 420-0853, Japan
  • GSK Investigational Site
    Tokyo, 142-8666, Japan
  • GSK Investigational Site
    ?Od?, 90-153, Poland
  • GSK Investigational Site
    Gdansk, 80-214, Poland
  • GSK Investigational Site
    Katowice, 40-611, Poland
  • GSK Investigational Site
    Krakow, 30-033, Poland
  • GSK Investigational Site
    Krakow, 31-513, Poland
  • GSK Investigational Site
    Lubin, 59-300, Poland
  • GSK Investigational Site
    Nadarzyn, 05-830, Poland
  • GSK Investigational Site
    Poznan, 60-355, Poland
  • GSK Investigational Site
    Strzelce Opolskie, 47-100, Poland
  • GSK Investigational Site
    Brasov, 500091, Romania
  • GSK Investigational Site
    Brasov, 500283, Romania
  • GSK Investigational Site
    Bucharest, 014146, Romania
  • GSK Investigational Site
    Bucharest, 014452, Romania
  • GSK Investigational Site
    Cluj-Napoca, 400349, Romania
  • GSK Investigational Site
    Timișoara, 300643, Romania
  • GSK Investigational Site
    Barcelona, 08022, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Barcelona, 08041, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Jerez de la Frontera, 11407, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Pamplona, 31008, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Seville, 41009, Spain
  • GSK Investigational Site
    Valladolid, 47005, Spain
  • GSK Investigational Site
    Zaragoza, 50009, Spain
  • GSK Investigational Site
    Gothenburg, SE-413 45, Sweden
  • GSK Investigational Site
    Lund, SE-221 85, Sweden
  • GSK Investigational Site
    Stockholm, SE-114 86, Sweden
  • GSK Investigational Site
    Stockholm, SE-171 76, Sweden
  • GSK Investigational Site
    Ankara, 06230, Turkey (Türkiye)
  • GSK Investigational Site
    CapaIstanbul, 34093, Turkey (Türkiye)
  • GSK Investigational Site
    Izmir, 35330, Turkey (Türkiye)
  • GSK Investigational Site
    Tekirdağ, 59100, Turkey (Türkiye)
09

References and documents

Publications

  • Gevaert P, Cornet M, Mullol J, De Corso E, Keles Turel N, Desrosiers M, et al. . ANCHOR-1/-2 primary data including pooled analysis ms. Lancet. PMID: 40037388 DOI: 10.1016/S0140-6736(25)00197-7
  • Jackson DJ, Bourdin A, Blackorby A, Leslie A, Vichiendilokkul A, Howarth P, Karkoszka N, Fujieda S, Cornet M. Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2. Adv Ther. 2026 Feb;43(2):880-897. doi: 10.1007/s12325-025-03457-4. Epub 2025 Dec 29. PubMed 41461999 ↗
  • Gevaert P, Desrosiers M, Cornet M, Mullol J, De Corso E, Keles Turel N, Maspero J, Fujieda S, Zhang L, Sousa AR, Woods SJ, Davis AM, Schalkwijk S, Edwards D, Ranganathan P, Follows R, Marshall C, Han JK; ANCHOR-1 and ANCHOR-2 trial investigators. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet. 2025 Mar 15;405(10482):911-926. doi: 10.1016/S0140-6736(25)00197-7. Epub 2025 Mar 1. PubMed 40037388 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jul 2024, 26 months.

Results were first posted in Sep 2025, 1 year 1 month after primary completion.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 26 months is above that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 16, 2022
StartActual
Apr 18, 2022
Primary completionActual
Jul 12, 2024
CompletionActual
Aug 6, 2024
Results first posted
Sep 9, 2025
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05281523
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 16, 2022
Start date
Apr 18, 2022
Primary completion
Jul 12, 2024
Completion
Aug 6, 2024
Results posted
Sep 9, 2025
Last update
Sep 9, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion